EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients.
Recent Searches
Life sciences
Our Global Life Sciences sector can help you navigate forward and achieve sustainable success in the new health-outcomes-driven ecosystem.
Our latest thinking
Pulse of the MedTech Industry Report
EY MedTech report on dealmaking, financing and state of the industry, with insights on growth and commercial strategies, AI, consumer and more.
EY Biotech Beyond Borders Report 2025
Biotech companies and life sciences leaders are managing uncertainty and preparing to bounce back across the biotechnology landscape. Find out how.
How life sciences can make the right deals in a time of change
Life sciences companies are returning to dealmaking amid cost and revenue pressures – how will they find the right deals to secure value? Learn more.
How early diagnosis can transform health care
Mirxes’ Dr. Zhou Lihan shares his purpose and passion for a more proactive approach to medicine. Learn more.
How life sciences businesses transform the tax and finance function
Life sciences organizations operate in a complex industry – one that looks set to become more challenging, including from a tax perspective. Learn more.
How CDMOs are leading innovation for pharmaceutical partners
Discover how CDMO M&A trends show CDMOs are becoming emerging technology leaders for pharmaceutical partners.
How to navigate global TP controversy in life sciences — Asia-Pacific and Europe focus
In this webcast, panelists discuss life sciences transfer pricing controversy trends and developments in Asia-Pacific and Europe. Learn more.
How to navigate global TP controversy in life sciences — US focus
In this webcast, panelists discuss life sciences transfer pricing controversy trends and developments in the US. Learn more.
How to navigate EU regulations for drug-device combination products
The new EU Medical Device Regulation (MDR) creates significant regulatory challenges for drug-device combination (DDC) product manufacturers.
How to account for outcome-based payment arrangements in life sciences
The use of outcome-based payment arrangements in the life sciences sector is growing in many jurisdictions, especially across Europe.
How AI can support decision-making in drug development portfolios
For the pharmaceutical industry, AI can be a powerful tool to drive better-informed asset portfolio decisions.
Optimizing health outcomes for all
Discover key insights that highlight strategic priorities and investments to enhance care across sectors, along with the evolution of organizational capabilities, based on a survey of 500 industry leaders.
How EY can Help
-
The EY Promotional Content Management Services team can provide you with support that will transform your processes and improve your results. Learn more.
Read more -
The EY Smart Reviewer can help your business accelerate and optimize the review and approval process for marketing and promotional materials. Find out how.
Read more -
Our Biopharma Launch Edge team can help your business achieve successful launches. Find out how.
Read more - Read more
- Read more
-
EY-Parthenon Health and Wellness Strategy Consulting teams help develop and deliver growth, transaction, digital and value creation strategies. We help health and life sciences organizations build greater financial and operational resilience and technical agility, supporting their future growth within an ever-changing landscape.
Read more
Direct to your inbox
Stay up to date with our Editor's picks newsletter.
Case studies
How Medtronic’s optimized supply chain gets products to patients in need
A global technology Life Sciences leader improved their supply chain planning to better serve patients. Learn more in this case study.
How St James’s Hospital's transformed cancer care
Learn how our client modernized its infrastructure enhancing its data management and speeding up cancer diagnostics.
How tech and trust transformed a tax operating model
Global pharmaceutical player Boehringer Ingelheim is reimaging its tax operating model to boost quality and efficiency. Learn more in this case study.